Comparison of direct in-house cerebrospinal fluid cytology with commercial pathology results in dogs.

OBJECTIVES: To investigate the correspondence between in-house direct cytological assessment of cerebrospinal fluid and results from a commercial veterinary pathology laboratory. METHODS: Prospective inclusion of samples from dogs that were presented for investigation of suspected neurological disease and had cerebrospinal fluid samples submitted to a commercial pathology laboratory for analysis. A board-certified veterinary pathologist assessed all cerebrospinal fluid samples, and a line smear was assessed in-house by two observers. Nucleated cell count, red blood cell count and differential cell counts were recorded and compared. RESULTS: In-clinic and commercial pathology nucleated cell counts and red blood cell counts were strongly correlated. In-house line smear results were compared with the gold standard of a defined dichotomous rating of 'increased nucleated cell count' provided by the external pathology service. Sensitivity was 93% and specificity 80% for samples with at least two cells per linear field. CLINICAL APPLICATION: Although not a replacement for the assessment of cerebrospinal fluid samples by specialist veterinary pathologists, this method can provide rapid and clinically meaningful information before externally processed sample results are available.

In vitro and in vivo irreversible blockade of cortical S2 serotonin receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline: a technique for investigating S2 serotonin receptor recovery.

N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) treatment, both in vitro and in vivo, results in an irreversible blockade of cortical S2 5-hydroxytryptamine (serotonin) receptors. Incubation of rat cortical homogenates with EEDQ in vitro results in a concentration-dependent (EC50 approximately 5 microM) and time-dependent decrease in the Bmax of [3H]ketanserin-labeled S2 serotonin receptors. Extensive washing of the homogenate following in vitro or in vivo EEDQ treatment does not result in an increase in the amount of [3H]ketanserin binding, indicating that EEDQ acts to modify irreversibly cortical S2 serotonin receptors. That the modification of S2 receptor binding by EEDQ occurs at the recognition site of the receptor is indicated by the finding that coincubation with the S2 receptor antagonist ketanserin, but not the D2 3,4-dihydroxyphenylethylamine (dopamine) receptor antagonist domperidone, selectively protects against the irreversible blockade of S2 serotonin receptors. Peripheral administration of EEDQ results in a dose-dependent reduction in cortical S2 serotonin receptors with maximal effects (approximately 90% reduction) observed following 10 mg/kg (i.p.). Seven days following peripheral administration of EEDQ there is a recovery of S2 serotonin receptors back to 74% of the original receptor population. These data demonstrate that EEDQ in vitro and in vivo acts as an irreversible antagonist of S2 serotonin receptors and that it can be used to investigate the recovery rate of these receptors.